No Detail Found!

Detection of anti-erythropoietin antibodies in patients with chronic renal failure undergoing hemodialysis

Author(s)
SADIA FARHAD Department of Pathology, Bacha Khan Medical College, Mardan Pakistan
INAM-U-LLAH The University of Haripur,KPK, Pakistan
K. SURESH BABU Symbiosis Medical College for Women, Symbiosis International (Deemed University), Pune,
SIDRA WALI National Institute of Health,Chak Shahzad Islamabad, Pakistan
BUSHRA TAHREEM University of Management and Technology,Lahore, Pakistan
IZBA AMJAD University of Management and Technology,Lahore, Pakistan
SANA KHALID University of Management and Technology,Lahore, Pakistan
FARES MOHAMMED SAEED MUTHANNA Department of Pharmaceutical Care, School of Pharmacy, Walailak University, Nakhon Si Thammarat, 80160, Thailand
Abstract
Background: Erythropoietin, a hormone produced by the kidney, activates the bone marrow upon demand. Recombinant erythropoietin can be subcutaneously injected to maintain red blood cell counts in chronic renal failure patients. Some time being recognized as foreign antigens, the patient occasionally produces antibodies against erythropoietin. Objective of current study was to investigate the existence of Anti-Erythropoietin Antibodies in Chronic Renal Failure (CRF) affected individuals during hemodialysis. Methods: The current study was performed at the Pathology Department, Khyber Teaching Hospital, Peshawar, Pakistan. After the assent of ethical committee, data collection was initiated to carry out the study. All the patients filled the informed consent proforma. The blood sample was collected in two EDTA and Gel tubes for complete blood count and for anti-EPO-antibodies respectively. ELISA tests for anti-EPO antibodies were performed on all patients who were classified into two groups based on whether antibodies were present or not. The data was analyzed using SPSS version 25.0. Results: In this study, 150 patients suffering from Chronic Kidney Disease on dialysis were included in which 79 (52.7%) were males. Moreover, age-wise group 41-60 years (n=93, 62%) were more suffering as compared to age group 21-40 years (n=24, 16%). In our study, hypertension was found to be a leading cause of death for 65(43.3%), diabetes 32(21.3%), hypertension and diabetes mellitus 10(6.7%), and miscellaneous accounted for 28.7%. There were 56(37.3%) patients who received dialysis twice a week, and 94 patients (62.6%) received it three times a week. Patients had transfusion history were 136(90.7%), while 92 (61.3%) patients were found to have anti-EPO antibodies. Conclusion: Anti-EPO antibodies are frequently demonstrated in patients with CKD undergoing hemodialysis. Due to the lack of correlation between antibody levels and Hb or reticulocyte counts, these antibodies might not be neutralizing antibodies.
Publication Details
Page(s) 1256-1259
Published Journal: Pakistan Journal of Medical and Health Sciences, Volume: 16, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
Hypertension, Peshawar., Chronic Renal Failure, Anti-EPO antibodies
0

Citations

0

Downloads

80

Views